Is there a correlation between Nicotinamide Adenine Dinucleotide (NAD) levels and the severity of atopic dermatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

There is limited direct evidence to suggest a correlation between NAD levels and the severity of atopic dermatitis, and current guidelines primarily focus on the management of atopic dermatitis through phototherapy and systemic therapies. The provided evidence does not directly address the relationship between Nicotinamide Adenine Dinucleotide (NAD) levels and atopic dermatitis severity. However, it discusses the management and treatment of atopic dermatitis, emphasizing the use of emollients, topical anti-inflammatory therapies, phototherapy, and systemic agents for more severe cases 1.

Understanding Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2–3% of adults, often associated with elevated serum immunoglobulin (IgE) levels and a personal or family history of type I allergies, allergic rhinitis, and asthma 1. The management of AD involves diagnosis, assessment, and treatment strategies that may include topical therapies, phototherapy, and systemic agents for severe cases.

NAD and Atopic Dermatitis

While the direct correlation between NAD levels and atopic dermatitis severity is not well-established in the provided evidence, understanding the role of NAD in cellular energy production and DNA repair suggests that its depletion could potentially impair skin cell function and exacerbate inflammatory responses. Some research outside the provided evidence indicates that NAD precursors like nicotinamide (vitamin B3) may help improve symptoms when applied topically or taken orally, though typical dosing and efficacy can vary.

Recommendations for Management

Given the current state of evidence, the management of atopic dermatitis should follow established guidelines that prioritize the use of emollients, topical anti-inflammatory therapies, and, for more severe cases, phototherapy and systemic agents. Patients should consult healthcare providers before starting any new regimen, including NAD-boosting treatments, as individual responses can vary and more clinical studies are needed to establish definitive treatment protocols. Lifestyle factors that support overall health, including regular exercise, adequate sleep, and reducing sun exposure, may complement other atopic dermatitis treatments.

Future Directions

Further research is necessary to fully understand the potential correlation between NAD levels and atopic dermatitis severity, as well as the efficacy of NAD-boosting regimens in managing AD symptoms. Until more direct evidence is available, healthcare providers should rely on established guidelines for the management of atopic dermatitis, considering the severity of the disease, its impact on the patient, and the efficacy, safety, and accessibility of available interventions 1.

From the Research

Correlation between NAD and Atopic Dermatitis

  • There is limited direct evidence on the correlation between Nicotinamide Adenine Dinucleotide (NAD) levels and the severity of atopic dermatitis.
  • However, studies have shown that nicotinamide, a form of vitamin B3, has moisturizing effects on atopic dry skin and can improve skin barrier function in atopic dermatitis 2.
  • Nicotinamide mononucleotide (NMN), a precursor to NAD, has been shown to ameliorate atopic dermatitis-like symptoms in mice by blocking the activation of ROS-mediated JAK2/STAT5 signaling pathway 3.
  • The severity of atopic dermatitis has been studied using various disease-severity and quality-of-life instruments, including SCORAD, EASI, and CDLQI 4, 5.
  • Molecular studies have shown that atopic dermatitis is characterized by immune dysfunction and epidermal barrier disruption, with increased levels of TH2, TH22, TH1, and TH17 cell-related mediators in lesional and nonlesional skin 6.

NAD and Atopic Dermatitis Severity

  • There is no direct evidence on the correlation between NAD levels and the severity of atopic dermatitis.
  • However, studies have shown that nicotinamide and NMN can have anti-atopic activities and improve skin barrier function in atopic dermatitis 3, 2.
  • Further research is needed to investigate the relationship between NAD levels and the severity of atopic dermatitis.

Potential Mechanisms

  • The potential mechanisms by which NAD may be related to atopic dermatitis include its role in energy metabolism, oxidative stress, and immune function.
  • Nicotinamide and NMN have been shown to have anti-inflammatory and antioxidant effects, which may contribute to their anti-atopic activities 3, 2.
  • Further research is needed to fully understand the mechanisms by which NAD may be related to atopic dermatitis.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.